Gentherm Incorporated (Nasdaq: THRM) — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 1, 2021. This is an annual report, not a standalone fourth-quarter earnings release; the supplied filing text does not provide clear Q4-only financial results.
Business context
Gentherm develops thermal-management products for automotive comfort and battery systems, and patient temperature management. Automotive generated $870.0 million, approximately 95% of 2020 product revenue; Medical generated $43.1 million. The company operates globally and is exposed to vehicle production, customer demand, and supply-chain conditions.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Product revenue | $913.1 million | $971.7 million |
| Gross profit / margin | $268.1 million / 29.4% | $288.3 million / 29.7% |
| Operating income / margin | $89.2 million / 9.8% | $84.3 million / 8.7% |
| Net income | $59.7 million | $48.9 million |
| Diluted EPS | $1.81 | $1.47 |
| Operating cash flow | $110.7 million | $118.8 million |
| Capital expenditures | $17.2 million | $23.7 million |
Cash and cash equivalents were $268.3 million at year-end, versus $50.4 million in 2019. Total debt was $192.4 million, up from $80.6 million; $186.2 million was outstanding under the revolving credit agreement. The company reported $288.8 million of additional borrowing availability, subject to conditions, and compliance with debt covenants at year-end. It repaid a further $80.0 million of credit-agreement borrowings in January 2021. The company stated that available cash, operating cash flow, and borrowing capacity should meet operating, capital, and debt-service needs for at least 12 months.
Changes versus the prior year
- Revenue declined 6.0%, chiefly from lower automotive volumes. Automotive volume effects reduced revenue by $38.2 million; favorable foreign exchange partly offset declines, while pricing and other factors reduced revenue by $27.5 million.
- Gross margin edged down 0.3 percentage points. Lower material costs, improved manufacturing productivity, fixed-cost savings, and foreign exchange helped offset lower volumes and other costs.
- Operating income increased despite lower revenue, as net R&D, SG&A, and restructuring expenses declined. The 2019 comparison included $21.2 million of impairment losses and $1.6 million of net divestiture losses, neither repeated in 2020.
- Net income rose to $59.7 million; 2020 included a $2.3 million other-income benefit, primarily from a patent sale, and a $5.4 million foreign-currency loss. Income-tax expense included $3.4 million related to settlement and closure of international tax audits.
- Product mix was uneven: CCS revenue fell 4.7%, seat heaters fell 12.1%, while steering-wheel heaters rose 16.6%, electronics rose 12.0%, and Battery Performance Solutions rose 22.7%. Medical revenue was $43.1 million versus $36.9 million for the continuing patient-temperature-management business in 2019; comparisons are affected by prior divestitures and segment presentation changes.
Outlook, risks, and unusual items
- COVID-19 sharply disrupted production and operations in the first half of 2020; production recovered in the second half. Management emphasized continuing uncertainty in 2021, including the pace of recovery and operational impacts.
- IHS Markit forecast 12.1% growth in light-vehicle production across Gentherm’s key markets in 2021. This is an industry forecast, not company revenue or earnings guidance.
- Management reported approximately $940 million of 2020 automotive new-business awards measured as projected lifetime revenue. Awards are not firm orders or a revenue forecast and may not convert to sales.
- Semiconductor shortages, supplier delays, freight costs, customer concentration, automotive cyclicality, pricing pressure, foreign exchange, and debt-covenant compliance are significant risks. Lear and Adient accounted for 15% and 14% of product revenue, respectively.
- A manufacturing-footprint restructuring is expected to cost $16–$19 million in total, including $13–$16 million in cash expenditures, and is expected to be substantially completed by the end of 2021. Planned consolidations include North American electronics manufacturing and an Asian facility closure.
- The company authorized a new $150 million share-repurchase program through December 2023, but made no repurchases under it in 2020. It does not expect to pay cash dividends in the foreseeable future.
- The 2019 comparative financial statements were revised for an income-tax error relating to deferred-tax-asset realizability. Management characterized the error as immaterial; the revision increased 2019 net income by $11.4 million, to $48.9 million.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective. The auditor identified valuation of Medical-segment goodwill as a critical audit matter.
Investor verification priorities
- Review the audited statements and notes for cash composition, debt terms, covenant headroom, and the effect of the January 2021 debt repayment.
- Assess accounts-receivable growth and customer exposure: year-end receivables rose to $211.7 million, and Lear and Adient each represented 18% of receivables.
- Verify the assumptions behind the Medical goodwill valuation and monitor Medical-segment results and growth.
- Track semiconductor availability, customer production schedules, and whether new-business awards convert into production revenue.
- Compare restructuring cash costs, completion timing, and realized savings with management’s $16–$19 million estimate.
- Review the deferred-tax revision and the realizability of the company’s deferred tax assets, reported at $72.2 million net.